In order to protect public health, the pharmacovigilance activities of the Agency should be adequately funded. It should be ensured that adequate funding is possible for pharmacovigilance activities by empowering the Agency to charge fees to marketing authorisation holders. However, the management of those collected funds should be under the permanent control of the Management Board in order to guarantee the independence of the Agency.
Recital 13, Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 Decembe…
In forcesince 15 Dec 2010